Erste Asset Management GmbH Invests $3.22 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Erste Asset Management GmbH bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 18,200 shares of the company's stock, valued at approximately $3,224,000. Erste Asset Management GmbH owned approximately 0.06% of Krystal Biotech as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Jamison Private Wealth Management Inc. acquired a new position in Krystal Biotech during the 2nd quarter worth $28,000. Key Financial Inc acquired a new stake in Krystal Biotech in the 2nd quarter valued at approximately $28,000. GAMMA Investing LLC lifted its stake in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares during the period. Blue Trust Inc. boosted its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $53,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Evercore ISI raised their price target on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $202.29.

Krystal Biotech Price Performance

Shares of KRYS traded down $8.94 during trading hours on Tuesday, hitting $185.97. The company's stock had a trading volume of 295,094 shares, compared to its average volume of 323,777. The company has a market cap of $5.35 billion, a price-to-earnings ratio of 105.07 and a beta of 0.80. Krystal Biotech, Inc. has a 52-week low of $100.98 and a 52-week high of $219.34. The business has a 50 day simple moving average of $180.92 and a two-hundred day simple moving average of $184.26.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the firm posted ($0.67) EPS. The firm's revenue was up 879.9% compared to the same quarter last year. Research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).